Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03200977 · ClinicalTrials.gov registry record
Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With Nivolumab
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 95
- Enrollment target
NCT03200977: Completed study, sponsored by Bristol-Myers Squibb.
NCT03200977 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 95 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03200977 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 95 participants
- Enrollment target
Study Summary
An observational database analysis, using existing data of patients diagnosed with Classical Hodgkin Lymphoma.
Primary Outcome
Treatment-Related Mortality at 6 months after an allogeneic Hemaetopoietic Cell Transplantation (HCT) among patients with cHL who were previously treated with nivolumab
Interventions
- OTHER Non-Interventional
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2016-07-01 |
| Est. Completion | 2022-06-03 |
What the finished NCT03200977 record still lists
NCT03200977 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 95 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Non-Interventional is the first listed.
NCT03200977 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03200977 about?
NCT03200977 is a clinical study titled "Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With Nivolumab". An observational database analysis, using existing data of patients diagnosed with Classical Hodgkin Lymphoma.
What is the current status of trial NCT03200977?
This trial is currently completed. The enrollment target is 95 participants. The study started on 2016-07-01. Estimated completion is 2022-06-03.
What interventions are being tested in trial NCT03200977?
The interventions under investigation include: Non-Interventional (OTHER).
Who is sponsoring clinical trial NCT03200977?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03339128 · 95 participants · Phase 2
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
- NCT03509961 · 95 participants · Phase 2
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- NCT03694756 · 95 participants · NA
TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer
- NCT04206215 · 95 participants · NA
Noninvasive Brain Stimulation for Treating Carpal Tunnel Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI